Meta analysis of curative effect and safety of different doses of ambroxol for lung cancer patients in perioperative period

Feng Li; Wang Aiping

doi:10.3969/j.issn.1009-6493.2015.31.005

Abstract：Objective:To systematically assess the curative effect and safety of different doses of ambroxol for lung cancer patients in perioperative period.Methods:The randomised or quasi randomized controlled trials RCTs)on the application of different doses of ambroxol for lung cancer patients in perioperative period were searched from the Cochrane Library,MEDLINE,Embase,CBM,CNKI,WanFang database from inception to August 1,2014.According to the Cochrane system evaluation method,the Data extraction and quality assess-ment were carried out in the included researches.The RevMan 5.3 software was used for meta analysis.Re-sults:Seven pieces of Chinese literatures were included and totally 523 patients (large dose group with 271 ca-ses,conventional dose group with 252 cases).Meta analysis results showed:Large dose of ambroxol significantly reduced the relative risk ratio of pulmonary atelectasis incidence[RR=0.22,5% CI (0.12,0.41)],relative risk ratio of pulmonary infection incidence[RR =0.33,5% CI (0.21,0.53),relative risk ratio of total pulmonary complications incidence[RR=0.28,5% CI (0.20,0.40)],shortened antibiotic use time[WMD=-1.69,5% CI (-2.1 9,-1.1 9)]and postoperative hospital time [WMD=-3.18,5% CI (-3.87,-2.48)].The incidence of adverse reactions of large doses of ambroxol group was higher than that in conventional dose group,but the difference were not statistically significant.Conclusion:Large dose ambroxol may improve the postoperative re-spiratory system symptoms,reduce pulmonary complications,protect the perioperative pulmonary function,ac-celerate the rehabilitation of patients and it was relatively safety.The evidence of this study was lower,still may not determine the optimal dosage,timing and indications,which need to be further studied.